Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 451 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ritonavir (rtv) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications

NCT00877591
View directory record Official record
Conditions
Opioid Dependency, HIV Infections
Interventions
Fosamprenavir/Ritonavir, Darunavir/Ritonavir, Rifampin, Rifabutin, Buprenorphine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 15, 2026, 9:48 AM EDT
Completed Phase 1 Interventional

Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns

NCT00000920
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Ritonavir, Saquinavir, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
14
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 15, 2026, 9:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents

NCT00766597
View directory record Official record
Conditions
HIV Infections
Interventions
Vicriviroc
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 15, 2026, 9:48 AM EDT
Completed Phase 3 Interventional Results available

A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects

NCT00296504
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
fosamprenavir (GW433908), ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
13 Years and older
Enrollment
753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
10
States / cities
Fountain Valley, California • San Francisco, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 15, 2026, 9:48 AM EDT
Completed Not applicable Interventional

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

NCT00000919
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Hydroxyurea, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
63
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 15, 2026, 9:48 AM EDT
Completed Phase 1 Interventional

Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients

NCT00000906
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Saquinavir, Methadone hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 15, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Results available

RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms

NCT05965726
View directory record Official record
Conditions
Long COVID-19, Long COVID
Interventions
Paxlovid, Ritonavir, Nirmatrelvir-matching placebo
Drug
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 15, 2026, 9:48 AM EDT
Completed Phase 4 Interventional

Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients

NCT00384904
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir/Ritonavir, Atazanavir/Ritonavir + Famotidine, Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Voorhees Township, New Jersey • Chapel Hill, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2010 · Synced Oct 15, 2026, 9:48 AM EDT
Completed Phase 3 Interventional

Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

NCT00120393
View directory record Official record
Conditions
HIV Infections
Interventions
atazanavir/ritonavir +2 NRTIs (immediate Switch Group), LPV/r +2 NRTIs (Delayed/optional Switch Group)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
12
States / cities
Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2010 · Synced Oct 15, 2026, 9:48 AM EDT
Not listed No phase listed Observational

BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects

NCT00388492
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Bellos, Nicholaos C., M.D.
Individual
Eligibility
18 Years and older
Enrollment
45 participants
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2007 · Synced Oct 15, 2026, 9:48 AM EDT
Terminated Phase 2 Interventional Results available

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

NCT00090779
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine/ tenofovir disoproxil fumarate, Lopinavir/Ritonavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Torrance, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 15, 2026, 9:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism

NCT00259727
View directory record Official record
Conditions
Diabetes, HIV Infections, Insulin Resistance
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 72 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2009 · Synced Oct 15, 2026, 9:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men

NCT00063804
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, AMD070
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 15, 2026, 9:48 AM EDT
Withdrawn No phase listed Observational

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women

NCT01394133
View directory record Official record
Conditions
HIV Infected
Interventions
Tenofovir, Emtricitabine, Atazanavir, Ritonavir
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Oct 15, 2026, 9:48 AM EDT
Completed Phase 4 Interventional Results available

Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection

NCT00885664
View directory record Official record
Conditions
HIV Infections
Interventions
Truvada (tenofovir/emtricitabine), Kaletra (lopinavir/ritonavir)
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 15, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Results available

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects

NCT00654147
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir & Lopinavir/ritonavir, Raltegravir and emtricitabine/tenofovir
Drug
Lead sponsor
Margaret A. Fischl, M.D.
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Oct 15, 2026, 9:48 AM EDT
Terminated Phase 2 Interventional

GW873140 In Combination With Kaletra In HIV Infected Subjects

NCT00102778
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
GW873140, Kaletra (lopinavir/ritonavir)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Fountain Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 15, 2026, 9:48 AM EDT
Completed Phase 1 Interventional

The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet

NCT00766818
View directory record Official record
Conditions
Pregnancy, HIV
Interventions
Kaletra
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2011 · Synced Oct 15, 2026, 9:48 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects

NCT00743470
View directory record Official record
Conditions
HIV, Tuberculosis
Interventions
lopinavir/ritonavir, rifabutin
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Oct 15, 2026, 9:48 AM EDT
Terminated Phase 2 Interventional

IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)

NCT04575610
View directory record Official record
Conditions
COVID-19
Interventions
PF-06650833, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 15, 2026, 9:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors

NCT00720590
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Atazanavir, Lopinavir/ritonavir, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 15, 2026, 9:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers

NCT01514968
View directory record Official record
Conditions
Healthy Volunteer
Interventions
cyclosporine, danoprevir, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 15, 2026, 9:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir

NCT00000898
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2000
U.S. locations
4
States / cities
San Francisco, California • Stanford, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 15, 2026, 9:48 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

LAAM-HAART PET Imaging

NCT01935830
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[11c] LAAM, Ritonavir, Efavirenz
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 15, 2026, 9:48 AM EDT